Problems with anticoagulation for continuous renal replacement therapies

Complications of Dialysis

Volumn , Issue , 2000, Pages 215-240

  Davenport, Andrew ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 49749151574     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (94)

1. Macias WL, Clark WR. Azotemia control by extracorporeal therapy in patients with acute renal failure. New Horizons 1995; 3: 688-698.
2. Kramer P, Böhler J, Kehr A, Gröne HJ, Schrader J, Matthaei D, Scheler F. TransAm Soc Atif Intern Organs 1982; 28: 28-32.
3. Olbricht C, Mueller C, Schurek HJ, Stolte H. Treatment of acute renal failure in patients with multiple organ failure by continuous spontaneous hemofiltration. Trans Am Soc Artif Intern Organs 1982; 28: 33-37.
4. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous circuits in patients with combined acute renal and hepatic failure. Nephron 1994; 66: 431-437.
5. Tabuchi N, de Haan J, Gallandat Huet RC, Boonstra PW, van Oeveren W. Gelatin use impairs platelet adhesion during cardiothoracic surgery. Thromb Haemostasis 1995; 74: 1447-1151.
6. Blei A, Olafsson S, Webster S, Levy R. Complications of intracranial pressure monitoring in fulminant hepatic failure. Lancet 1993; 341: 157-158.
7. Atillasoy E, Berk PD. Extracorporeal liver support: historical background and critical analysis. In: Lee WM, Williams R, eds. Acute Liver Failure. Cambridge University Press, 1997: 223-244.
8. Ellis AJ, Sussman NL, Kelly JH, Williams R. Clinical experience with an extracorporeal liver assist device. In: Lee WM, Williams R, eds. Acute Liver Failure. Cambridge University Press, 1997: 255-266.
9. Hesselvik F, Blomback M, Brodin B, Maller R. Coagulation fibrinolysis and kallikrein systems in sepsis: relation to outcome. Crit Care Med 1989; 17: 724-733.
10. Hesselvik JF, Malm J, Dahlback B, Blomback M. Protein C, protein S and C4b binding protein in severe infection and septic shock. Thromb Hemostat 1991; 65: 126-129.
11. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
12. Rabelink TJ, Zwaginga JJ, Koomans HA, Sixma JJ. Thrombosis and hemostasis in renal disease. Kid Int 1994; 46: 287-296.
13. Hunt BJ. Acquired coagulation disorders. In: Weatherall DJ, Ledingham DJJ, Warrell DA, eds. Oxford Texbook of Medicine. 3d ed. Oxford Medical Publishers, 1996: 3653-3661.
14. Cazenave JP, Mulvihill. Interactions of blood with surfaces: hemocompatibility and thromboresistance of biomaterials. Contrib Nephrol 1988; 62: 118-127.
15. Neild GH, Barratt TM. Acute renal failure associated with microangiopathy. In: Davison AM, Cameron JS, Grünfeld J-P, Kerr DNS, Ritz E, Winearls CG, eds. Oxford Textbook of Renal Medicine. 2nd ed. Oxford Medical Publications, 1649-1666.
16. Schmidt B, Mujais SK. Evaluation of dialysis membrane- blood compatibility: experimental methods. Contrib Nephrol 1995; 113: 32-44.
17. Barraud F, Ferrand E, Hira M, Chagneau C, Pourrat O, Robert R. Variation of platelet count during continuous venovenous hemofiltration. Proceedings Continuous Hemofiltration Therapies in the ICU, Paris, 1996, p. 12.
18. Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 1994; 22: 1774-1781.
19. Martin PY, Chevrolet JC, Suter P, Favre H. Anticoagulation in patients treated by continuous veno-venous hemofiltration: a retrospective study. Am J Kidney Dis 1994; 24: 806-812.
20. Boldt J, Menges T, Wollbruck M, Sonneborn S, Hempelmann G. Continuous hemofiltration and platelet function in critically ill patients. Crit Care Med 1994; 22: 1150-1160.
21. Davenport A, Kirby SA. Hemofiltration/dialysis treatment in patients with acute renal failure. Care Crit Ill 1996; 12: 54-58.
22. Sloand JA, Sloand EM. Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 1997; 8: 799-803.
23. Churchill DN. Efficiency and biocompatibility of membranes. Contrib Nephrol 1995; 113: 60-71.
24. Hakim RM. Clinical implications of hemodialysis membrane biocompatibility. Kidney Int 1993; 44: 484-494.
25. Webb AR, Mythen MG, Jacobson D, Mackie IJ. Maintaining blood flow in the extracorporeal circuit: hemostasis and anticoagulation. Intensiv Care Med 1995; 21: 84-93.
26. Schmidt B, Mujais SK. Evaluation of dialysis membrane- blood compatibility: experimental methods. Contrib Nephrol 1995; 113: 32-44.
27. Langley PG, Keays R, Hughes RD, Forbes A, Delvos U, Williams R. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatol 1991; 14: 251-256.
28. Salmon J, Cardigan R, Mackie I, Cohen SL, Machin S, Singer M. Continuous venovenous hemofiltration using polyacrylonitrile filters does not activate contact system and inrinsic system coagulation pathways. Intensiv Care Med 1997; 23: 38-43.
29. Stefanidis I, Hägel J, Kierdorf H, Maurin N. Influencing hemostasis during continuous venovenous hemofiltration after acute renal failure: comparison with hemodialysis. Contrib Nephrol 1995; 116: 140-144.
30. Bellomo R, Teede H, Boyce N. Anticoagulant regimens in acute continuous hemodiafiltration: a comparative study. Intensiv Care Med 1993; 19: 329-332.
31. Davenport A. The coagulation system in the critically ill patient with acute renal failure and the effect of an extracorporeal circuit. Am J Kidney Dis 1997; 30(suppl 4): S20-27.
32. Holt AW, Bierer P, Berstein AD, Bury LJ, Vedig AE. Continuous renal replacement therapy in critically ill patients: monitoring circuit function. Anaesth Intens Care 1996; 24: 423-429.
33. Mehta RL. Anticoagulation strategies or continuous renal replacement therapies: what works? Am J Kidney Dis 1996; 28(suppl 3): S8-S14.
34. Gretz N, Quintel M, Ragaller M, Odenwälder W, Bender HJ, Rohmeiss P, Strauch M. Low-dose heparinization for anticoagulation in intensive care patients on continuous hemofiltration. Contrib Nephrol 1995; 116: 130-135.
35. Ronco C. Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 1993; 40: 187-198.
36. Golper TA. Continuous arteriovenous hemofiltration in acute renal failure. Am J Kidney Dis 1985; 6: 373-386.
37. Erdenm Y, Haznedaroglu IC, Celik I, Yalcin AU, Turgan C, Caglar S. Coagulation, fibrinolysis and fibrinolysis inhibitors in hemodialysis patients: contribution of arteriovenous fistula. Nephrol Dial Transplant 1996; 11: 1299-1305.
38. Olbricht CJ, Schurek HJ, Tytul S, Muller C, Stolte H. Comparison between Scribner shunt and femoral catheters as vascular access for continuous arteriovenous hemofiltration. In: Kramer P, ed. Arteriovenous Hemofiltration. Berlin: Springer-Verlag, 1985: 57-66.
39. Weiss L, Danielson BG, Wikström B, Hedstrand U, Wahlberg J. Continuous arteriovenous hemofiltration in the treatment of 100 critically ill patients with acute renal failure: report on clinical outcome and nutritional aspects. Clin Nephrol 1989; 31: 184-189.
40. Stevens PE, Davies SP, Brown EA, Riley B, Gower PE, Kox W. Continuous arteriovenous hemodialysis in critically ill patients. Lancet 1988; ii: 150-152.
41. Smoyer WE, McAdams C, Kaplan BS, Sherbottle JR. Determinants of survival in pediatric continuous hemofiltration. J Am Soc Nephrol 1995; 6: 1401-1409.
42. McLaughlin K, Jones B, Mactier R, Porteus C. Longterm vascular access for hemodialysis using silicon dual lumen catheters with guidewire replacement of catheters for technique salvage. Am J Kidney Dis 1997; 29: 553-559.
43. Jean G, Chazot C, Vanel T, Charra B, Terrat JC, Calemard E, Laurent G. Central venous catheters for hemodialysis: looking for optimal blood flow. Nephrol Dial Transplant 1997; 12: 1689-1691.
44. Favre H, Martin Y, Stoermann C. Anticoagulation in continuous extracorporeal renal replacement therapy. Semin Dial 1996; 9: 112-118.
45. Athirakul K, Conlon P, Schwab S. Cuffed central venous hemodialysis catheters and adequacy of dialysis. J Am Soc Nephrol 1996; 7: 1402.
46. Zobel G, Ring E, Kuttnig M, Grubbauer HM. Continuous arteriovenous hemofiltration versus continuous venovenous hemofiltration in critically ill pediatric patients. Contrib Nephrol 1991; 93: 257-260.
47. Cicchetti T, Senatore RP, Fransima F, Ferrari S, Striano U, Milei M, Cosentino S. Dialysis treatment using an ethylene vinyl alcohol membrane and no anticoagulation for chronic uremic patients. Artif Organs 1993; 17: 816-819.
48. Zobel G, Ring E, Rödel S. Prognosis in pediatric patients with multiple organ system failure and continuous extracorporeal renal support. Contrib Nephrol 1995; 116: 163-168.
49. Davenport A, Will EJ, Davison AM. The effect of the direction of dialysate flow on the efficiency of continuous arteriovenous hemodialysis. Blood Purif 1990; 8: 329-336.
50. Turitto VT, Weiss HJ, Baumgartner HR. Rheological factors influencing platelet interaction with vessel wall surfaces. J Rheol 1979; 23: 735-749.
51. Aarts PAMM, Heethaar RM, Sixma JJ. Red blood cell deformibility influences platelet vessel wall interaction in flowing blood. Blood 1983; 62: 214-217.
52. Olbricht CJ, Haubitz M, Häbel U, Frei U, Koch K-M. Continuous arteriovenous hemofiltration: in vivo functional characteristics and its dependence on vascular access and filter design. Nephron 1990; 55: 49-57.
53. Yohay DA, Butterly DW, Schwab SJ, Quarles LD. Continuous arteriovenous hemodialysis: effect of dialyzer geometry. Kidney Int 1992; 42: 448-451.
54. Van der Wetering J, Westendorp RGJ, van der Hoeven JG, Stolk B, Feuth JDM, Chang PC. Heparin use in continuous renal renal replacement therapies: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7: 145-150.
55. Silvester W, Honoré P, Sieffert E, Valentine J, Wagle S, Smithies M, Bihari D. Effect of heparin, prostacyclin or combination, and effect of polyacrylonitrile or polysulphone membranes on filter survival in critically ill patients on continuous venovenous hemofiltration. Proceedings Continuous Hemofiltration Therapies in the ICU, Paris, 1996, p. 16.
56. Lang S, Küchle C, Fricke H, Schiffl H. Biocompatible intermittent hemodialysis. New Horizons 1995; 3: 680-687.
57. Lane DA, Bowry SK. The scientific basis for selection of measures of thrombogenicity. Nephrol Dial Transplant 1994; 9(suppl 2): 18-28.
58. Kaplan AA, Longnecker RE, Folkert VW. Suction assisted continuous arteriovenous hemofiltration. Trans Am Soc Artif Intern Organs 1983; 29: 408-413.
59. Kaplan AA. Continuous arteriovenous hemofiltrationand related therapies. In: Jacobs C, Kjellstrand KE, Koch KM, Winchester JF, eds. Replacement of Renal Function by Dialysis. 4th ed. Boston: Kluwer Academic Publishers, 19xx: 390-417.
60. David S, Cambi V. Hemofiltration: predilution versus post dilution. Contrib Nephrol 1992; 96: 77-85.
61. MacLean AG, Goddard J, Harber M, Niadoo R, Davenport A, Sweny P. Lactate free dialysate for continuous hemodiafiltration. Effects on control of acidosis, blood pressure and inotrope requirement. Am Soc Nephrol 1996; 7: 1413.
62. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 1990; 38: 976-981.
63. Ward DM, Mehta RL. Extracorporeal management of acute renal failure patients at risk of high bleeding. Kidney Int 1993; (suppl 41): S237-S244.
64. Samuelsson O, Amiral J, Attman P-O, Bennegård K, Biörck S, Larsson G, Tengborn L. Heparin-induced thrombocytopenia during continuous hemofiltration. Nephrol Dial Transplant 1995; 10: 1768-1771.
65. Ronco C, Brendolan A, Bragantini L, Chiaramonte S, Feriani M, Fabris A, Dell’Aquila R, LaGreca G, Milan M. Continuous arteriovenous hemofiltration with AN69S membrane; procedures and experience. Kidney Int 1988; 33(suppl 24): S150-S153.
66. Mulvihill JN, Cazenave JP, Faradji A, Oberling F. Reduction de l’adhesion des plaquettes et de la formation d’un thrombus dans les circuits extracorporels de plasmapherese apres passivation des surfaces par l’albumine. 8eme Congr int CEC, Paris, 1983, p. 134.
67. Ellis A, Wendon JA, Williams R. Effect of albumin priming on hemofiltration circuits. 13th European Crit Care Meeting, Athens, 1996, p. 362.
68. Reeves JH, Seal PF, Voss AL, O’Connor C. Albumin priming does not prolong hemofilter life. ASAIO J 1997; 43: 193-196.
69. Singer M, McNally T, Screaton G, Mackie I, Machin S, Cohen SL. Heparin clearance during continuous venovenous hemofiltration. Intensive Care Med 1994; 20: 212-215.
70. Nurmohamed MT, Knipscheer HC, Stevens P, Krediet RT, Roggekamp MC, Berckmans, ten Cate JW. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic dialysis patients. Clin Nephrol 1993; 39: 166-171.
71. Vanholder RC, Camez AA, Veys NM, Soria J, Mirshahi M, Sorai C, Ringoir R. Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. Kidney Int 1994; 1754-1759.
72. Morikawa K, Akizawa T, Koshikawa S. Application for FUT-175, protease inhibitor, for an anticoagulant to hemodialysis. Jpn J Artif Organs 1983; 12: 75.
73. Zobel G, Trop M, Muntean W, Ring E, Gleispach TA. Anticoagulation for continuous arteriovenous hemofiltration in children. Blood Purif 1988; 6: 90-95.
74. Mackie IJ, Bull HA. Normal hemostasis and its regulation. Blood Rev 1989; 3: 237-250.
75. Ward DM. The approach to anticoagulation in patients treated with extracorporeal therapy in the ICU. Adv Renal Replacement Ther 1997; 4: 160-173.
76. Bastien O, French P, Paulus S, Filley S, Berruyer M, Dechavanne M. Antithrombin III deficiency during continuous veno-venous hemofiltration. Contrib Nephrol 1995; 116: 154-158.
77. Stiekema JC, Van Griensen JM, Van Dinther TG, Cohen AF. A cross over comparison of the anti-clotting effects of three low molecular weight heparins and glycosaminoglycuron. Br J Clin Pharmacol 1993; 36: 51-56.
78. Jeffrey RF, Khan AA, Douglas JT, Will EJ, Davison AM. Anticoagulation with low molecular weight heparin (fragmin) during continuous hemodialysis in the intensive care unit. Artif Organs 1993; 17: 717-720.
79. Wynckel A, Bernieh B, Toupance O, N’Guyen PH, Wong T, Lavaud S, Chanard J. Guidelines to the use of enoxparin in slow continuous dialysis. Contrib Nephrol 1991; 93: 221-224.
80. Hory B. Hemodialysis with low molecular weight heparin versus standard heparin to standard heparin in hemodialysis/hemofiltration. Am J Med 1988; 84: 566-567.
81. Davenport A. CRRT in the management of patients with liver disease. Seminar Dial 1996; 9: 78-84.
82. Vun CM, Evans S, Chong BH. Cross reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia. Thromb Res 1996; 81: 525-532.
83. Nurmohamed MT, Knipscheer HC, Stevens P, Krediet RT, Roggekamp MC, Berckmans RJ, Ten Cate JW. Clinical experience with a new antithrombotic (dermatan sulfate) in chronic hemodialysis patients. Clin Nephrol 1993; 39: 166-171.
84. von dem Borne PA, Meijers JC, Bouma BN. Effect of heparin on the activation of factor XI by fibrin bound thrombin. Thromb Haemostasis 1996; 76: 347-353.
85. Mahul P, Raynaud J, Favre JP, Jospe R, Decousus H, Auboyer C. Heparin-induced thrombopenia during hemodialysis in intensive care: use of a low molecular weight heparinoid, ORG 10172 (Orgaran). Ann Fr Anesth Reanim 1995; 14: 29-32.
86. Bannan S, Danby A, Cowan D, Ashraf S, Martin PG. Low heparinization with heparin-bonded bypass circuits: is it a safe strategy? Ann Thorac Surg 1997; 63: 663-668.
87. Sieffert E, Matéo J, Deligeon N, Payen D. Continuous venovenous hemofiltration using heparin coated or non heparin coated membranes in critically ill patients. Proceedings Continuous Hemofiltration Therapies, Paris, 1996, pp. 14-15.
88. Davenport A, Worth DP, Will EJ. Hypochloraemic alkalosis after high flux continuous hemofiltration and continuous arteriovenous hemofiltration with dialysis. Lancet 1988; i: 658.
89. Nowak MA, Campbell TE. Profound hypercalcaemia in continuous venovenous hemofiltration dialysis with trisodium citrate anticoagulation and hepatic failure. Clin Chem 1997; 43: 412-413.
90. Ellis A, Wendon J. Circulatory, respiratory, cerebral and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis 1996; 16: 379-388.
91. Davenport A, Will EJ, Davison EM. The effect of prostacyclin on intracranial pressure in patients with acute hepatic and renal failure. Clin Nephrol 1991; 25: 151-157.
92. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K, Kitamurs. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodialysis. Contrib Nephrol 1991; 93: 215-217.
93. Shigemoto T, Shimaoka H, Atagi K, Satani M. Optimal anticoagulation during continuous hemofiltration and continuous hemodialysis for patients with multiple organ failure. Jpn J Artif Organs 1994; 23: 380-384.
94. Palevsky PM, Burr R, Moreland L, Tokiwa Y, Greenberg A. Failure low molecular weight dextran to prevent clotting during continuous renal replacement therapy. ASAIO J 1995; 41: 847-849.